INT79357

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1999
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 32
Total Number 33
Disease Relevance 16.06
Pain Relevance 1.35

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (ERVW-1)
Anatomy Link Frequency
outer layer 2
macrophage 1
plasma 1
neurons 1
ERVW-1 (Homo sapiens)
Pain Link Frequency Relevance Heat
addiction 286 98.72 Very High Very High Very High
chemokine 36 98.46 Very High Very High Very High
Glutamate 2 97.68 Very High Very High Very High
Glutamate receptor 1 96.72 Very High Very High Very High
tetrodotoxin 1 94.56 High High
drug abuse 8 93.88 High High
Central nervous system 61 88.76 High High
opiate 2 75.00 Quite High
cytokine 82 64.32 Quite High
Nerve growth factor 2 45.60 Quite Low
Disease Link Frequency Relevance Heat
Acquired Immune Deficiency Syndrome Or Hiv Infection 1613 100.00 Very High Very High Very High
Sprains And Strains 159 100.00 Very High Very High Very High
Infection 708 99.62 Very High Very High Very High
Immunization 81 99.18 Very High Very High Very High
Toxicity 22 99.04 Very High Very High Very High
Viral Meningitis 66 96.28 Very High Very High Very High
Asymptomatic Infections 5 95.64 Very High Very High Very High
Disease 155 94.20 High High
Drug Dependence 8 93.88 High High
Chronic Fatigue Syndrome 116 93.52 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Thus, we hypothesize that the differences in sensitivity to inhibition of entry by HNG-105 may be caused by conformational variations between the Env, rather than diminished interaction with the inhibitor.
Env Binding (interaction) of
1) Confidence 0.43 Published 2008 Journal Retrovirology Section Body Doc Link PMC2576352 Disease Relevance 0.08 Pain Relevance 0
Included in these in vitro studies is a linkage or association of tissue damage and viral load with the actions HIV envelope protein gp120 with substances of abuse.
HIV envelope protein gp120 Binding (linkage) of associated with acquired immune deficiency syndrome or hiv infection
2) Confidence 0.42 Published 1999 Journal Arch. Immunol. Ther. Exp. (Warsz.) Section Abstract Doc Link 10202562 Disease Relevance 0.93 Pain Relevance 0.21
Thus, both immunization regimens elicited antibodies capable of binding to the native, oligomeric conformation of envelope as it exists on virions.
env Binding (binding) of associated with immunization
3) Confidence 0.36 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2621341 Disease Relevance 0.36 Pain Relevance 0
A 3.3 kb HIV fragment, spanning the env to the 3?
env Binding (spanning) of associated with acquired immune deficiency syndrome or hiv infection
4) Confidence 0.36 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2780293 Disease Relevance 0.16 Pain Relevance 0
Overall, there was no association of SIV envelope diversity as measured by entropy with either viral RNA levels or virus-specific neutralizing antibodies in plasma (see below and Fig. 5).
env Neg (no) Binding (association) of in plasma
5) Confidence 0.35 Published 2005 Journal Virol J Section Body Doc Link PMC552328 Disease Relevance 0.15 Pain Relevance 0
Antibodies bound to envelope were detected by an anti-human IgG fluorescent dye (Alexa Fluor 594 goat anti-human IgG, Invitrogen, Carlsbad, CA).


env Binding (bound) of
6) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2810329 Disease Relevance 0.60 Pain Relevance 0
Both immunization regimens elicited similar neutralizing antibody titers to a lab-adapted strain of SIVmac251, verifying the induction of antibodies capable of binding to the native, oligomeric conformation of envelope as it exists on virions.
env Binding (binding) of associated with immunization and sprains and strains
7) Confidence 0.35 Published 2009 Journal PLoS Pathogens Section Body Doc Link PMC2621341 Disease Relevance 1.04 Pain Relevance 0.03
This analysis has confirmed the goodness of our models for DS17 and SPL Env, since for both we obtained scores greater than zero throughout gp120 on the Verify3D plot.
Env Binding (goodness) of
8) Confidence 0.33 Published 2008 Journal Retrovirology Section Body Doc Link PMC2576352 Disease Relevance 0.23 Pain Relevance 0.07
Our results however demonstrate that, at least in these Env backgrounds, the determinants for increased fusogenicity and reduced sensitivity to fusion inhibitors lie in gp120 and overlap with those conferring low CD4 dependence, increased avidity for CD4 and enhanced macrophage tropism.
Env Binding (backgrounds) of in macrophage associated with addiction
9) Confidence 0.33 Published 2008 Journal Retrovirology Section Body Doc Link PMC2576352 Disease Relevance 0.19 Pain Relevance 0.13
In addition, asparagine in position 362 in gp120's C3 region, which has been found in a higher proportion of CCR5-using Env derived from AIDS patients than from individuals with asymptomatic infection, has been shown to contribute, albeit in a strain-dependent manner, to increased fusogenicity and higher sensitivity to an anti-CD4bs mAb, perhaps by promoting greater exposure of the CD4bs and/or stabilizing the CD4-bound Env conformation [91].
Env Binding (bound) of associated with asymptomatic infections, acquired immune deficiency syndrome or hiv infection and sprains and strains
10) Confidence 0.33 Published 2008 Journal Retrovirology Section Body Doc Link PMC2576352 Disease Relevance 0.65 Pain Relevance 0.03
Therefore, in this group of wild-type, chimeric and mutant Env high fusogenicity mostly correlates with low CD4 dependence and high avidity for CD4.
Env Binding (fusogenicity) of associated with addiction
11) Confidence 0.33 Published 2008 Journal Retrovirology Section Body Doc Link PMC2576352 Disease Relevance 0 Pain Relevance 0.09
Included in these in vitro studies is a linkage or association of tissue damage and viral load with the actions HIV envelope protein gp120 with substances of abuse.
HIV envelope protein gp120 Binding (association) of associated with acquired immune deficiency syndrome or hiv infection
12) Confidence 0.31 Published 1999 Journal Arch. Immunol. Ther. Exp. (Warsz.) Section Abstract Doc Link 10202562 Disease Relevance 0.93 Pain Relevance 0.20
We used a new WB assay to test for anti-XMRV antibodies and showed by using both monoclonal antibodies and polyclonal antisera that this assay detected specifically, and with high titers, reactivity to both XMRV and MuLV Gag and Env proteins.
Env Binding (reactivity) of
13) Confidence 0.29 Published 2010 Journal Retrovirology Section Body Doc Link PMC2908559 Disease Relevance 0.61 Pain Relevance 0
An analysis that includes sequences from specimens collected over time beginning with primary infection from three women, found the HIV-1 env sequences clustered by the sampling time as well as tissue type [7].
env Binding (found) of associated with acquired immune deficiency syndrome or hiv infection and infection
14) Confidence 0.29 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2741601 Disease Relevance 0.50 Pain Relevance 0
0.001 for Env; p?
Env Binding (0.001) of
15) Confidence 0.20 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981570 Disease Relevance 0 Pain Relevance 0.06
Both Env and Gag response rates were significantly greater than the Pol response rate (p?
Env Binding (greater) of
16) Confidence 0.20 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981570 Disease Relevance 0.06 Pain Relevance 0.07
ELISA measurement of serum IgG binding to Gag p24 or Env gp120
Env Binding (binding) of
17) Confidence 0.17 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981570 Disease Relevance 0.27 Pain Relevance 0
The entry of HIV-1 into target cells requires the binding of the viral envelope glycoprotein (Env) with the target cell CD4 and an additional target cell co-receptor 57.
viral envelope glycoprotein Binding (binding) of associated with acquired immune deficiency syndrome or hiv infection
18) Confidence 0.13 Published 2004 Journal International Journal of Medical Sciences Section Body Doc Link PMC1074710 Disease Relevance 0.53 Pain Relevance 0.04
The entry of HIV-1 into target cells requires the binding of the viral envelope glycoprotein (Env) with the target cell CD4 and an additional target cell co-receptor 57.
Env Binding (binding) of associated with acquired immune deficiency syndrome or hiv infection
19) Confidence 0.13 Published 2004 Journal International Journal of Medical Sciences Section Body Doc Link PMC1074710 Disease Relevance 0.53 Pain Relevance 0.04
The C46 targets HIV-1 env and the site I shRNA targets HIV-1 tat and rev which are all in the SHIV chimera and required for SHIV replication.


env Binding (targets) of associated with acquired immune deficiency syndrome or hiv infection
20) Confidence 0.12 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2765621 Disease Relevance 1.24 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox